Recombinant DNA-derived human insulin-like growth factor II (hIGF-II) stimulates growth in hypophysectomized rats

Endocr Res. 1989;15(3):403-11. doi: 10.3109/07435808909042749.

Abstract

Sustained subcutaneous administration of recombinant DNA-derived insulin-like growth factor II to immature female hypophysectomized rats stimulated significant increases in body weight gain, tibial epiphyseal cartilage width, femur hydroxyproline concentrations and a significant decrease in serum urea nitrogen concentrations. Recombinant DNA-derived human growth hormone (Humatrope), administered in the same manner produced similar biological effects. The data support the contention that hIGF-II has anabolic effects when administered to hypophysectomized rats and may be a locally acting mediator of pituitary hormone actions.

MeSH terms

  • Animals
  • Blood Urea Nitrogen
  • Body Weight / drug effects
  • Bone Development / drug effects
  • Bone and Bones / metabolism
  • Female
  • Growth / drug effects*
  • Growth Hormone / pharmacology
  • Humans
  • Hydroxyproline / analysis
  • Hypophysectomy*
  • Insulin-Like Growth Factor II / pharmacology*
  • Rats
  • Rats, Inbred Strains
  • Recombinant Proteins / pharmacology
  • Somatomedins / pharmacology*

Substances

  • Recombinant Proteins
  • Somatomedins
  • Insulin-Like Growth Factor II
  • Growth Hormone
  • Hydroxyproline